The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34402-34413

  Guo, Cong ^a   Su, Jia ^a   Li, Zhijun ^b   Xiao, Rui ^b   Wen, Jianxun ^b   Li, Yanyan ^c   Zhang, Meng ^a   Zhang, Xueting ^a   Yu, Donna ^d   Huang, Wendong ^d   Chen, Wei Dong ^b,c   Wang, Yan Dong ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bile acid receptor; Gastric cancer; Gpbar1; STAT3; TGR5

Indexed keywords

G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; GPBAR1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MIGRATION INHIBITION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; STOMACH CANCER; TRANSCRIPTION TERMINATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84946594940     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5353     Document Type: Article

References (33)

1. Ma SC, Zhao Y, Zhang T, Ling XL, Zhao D. Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. OncoTargets and therapy. 2015; 8:641-648.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
3. Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer letters. 2014; 355:106-112.
4. Lu J, Zhang L, Chen X, Lu Q, Yang Y, Liu J, Ma X. SIRT1 counteracted the activation of STAT3 and NF-kappaB to repress the gastric cancer growth. International journal of clinical and experimental medicine. 2014; 7:5050-5058.
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006; 355:11-20.
6. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30:2327-2333.
7. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer cell. 2009; 15:283-293.
8. Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. STAT3: a target to enhance antitumor immune response. Current topics in microbiology and immunology. 2011; 344:41-59.
9. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer cell. 2009; 16:487-497.
10. Yang Z, Guo L, Liu D, Sun L, Chen H, Deng Q, Liu Y, Yu M, Ma Y, Guo N, Shi M. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget. 2015; 6:5072-5087.
11. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. The Journal of biological chemistry. 2003; 278:9435-9440.
12. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2014; 46:302-312.
13. Wang YD, Chen WD, Yu D, Forman BM, Huang W. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology (Baltimore, Md). 2011; 54:1421-1432.
14. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. The Journal of clinical investigation. 2007; 117:60-69.
15. Tao YX. Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacology & therapeutics. 2008; 120:129-148.
16. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription (STAT) activation in prostate cancer: Direct STAT inhibition induces apoptosis in prostate cancer lines. Molecular cancer therapeutics. 2004; 3:11-20.
17. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, MuroCacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer research. 2002; 62:6659-6666.
18. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2001; 414:916-920.
19. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nature reviews Cancer. 2007; 7:79-94.
20. Tang Y, Chen Y, Jiang H, Robbins GT, Nie D. G-proteincoupled receptor for short-chain fatty acids suppresses colon cancer. International journal of cancer Journal international du cancer. 2011; 128:847-856.
21. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature reviews Cancer. 2009; 9:798-809.
22. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, Karras JG, Zhang H. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12:7140-7148.
23. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clinical cancer research: an official journal of the American Association for Cancer Research. 2002; 8:945-954.
24. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10:105-115.
25. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996; 379:645-648.
26. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9:316-326.
27. Shih YW, Lee YC, Wu PF, Lee YB, Chiang TA. Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase-plasminogen activator. Hepatology research: the official journal of the Japan Society of Hepatology. 2009; 39:998-1009.
28. Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, Poon RT, Fan ST, Man K. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. European journal of cancer. 2011; 47:2299-2305.
29. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, Weissenberger J. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. Journal of neurooncology. 2011; 101:393-403.
30. Wuertz K, Vo N, Kletsas D, Boos N. Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-kappaB and MAP kinases. European cells & materials. 2012; 23:103-119. discussion 119-120.
31. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006; 439:484-489.
32. Thomas C, Auwerx J, Schoonjans K. Bile acids and the membrane bile acid receptor TGR5-connecting nutrition and metabolism. Thyroid: official journal of the American Thyroid Association. 2008; 18:167-174.
33. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. International journal of obesity (2005). 2008; 32 Suppl 7:S52-54.